Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors.
hearing loss
oropharyngeal cancer
ototoxicity
survivorship
tinnitus
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
01 2023
01 2023
Historique:
revised:
28
04
2022
received:
25
03
2022
accepted:
02
05
2022
pubmed:
14
6
2022
medline:
20
1
2023
entrez:
13
6
2022
Statut:
ppublish
Résumé
This study investigated the association of hearing loss and tinnitus with overall health-related quality of life (HRQoL) among long-term oropharyngeal cancer (OPC) survivors. This study included OPC survivors treated between 2000 and 2013 and surveyed from September 2015 to July 2016. Hearing loss and tinnitus were measured by asking survivors to rate their "difficulty with hearing loss and/or ringing in the ears" from 0 (not present) to 10 (as bad as you can imagine). Hearing loss and tinnitus scores were categorized as follows: 0 for none, 1-4 for mild, and 5-10 for moderate to severe. The primary outcome was the mean score of MD nderson Symptom Inventory Head & Neck module interference component as a HRQoL surrogate dichotomized as follows: 0 to 4 for none to mild and 5 to 10 for moderate to severe interference. Among 880 OPC survivors, 35.6% (314), reported none, 39.3% (347) reported mild, and 25.1% (221) reported moderate to severe hearing loss and tinnitus. On multivariable analysis, mild (OR, 5.83; 95% CI; 1.48-22.88; p = 0.012) and moderate (OR, 30.01; 95% CI; 7.96-113.10; p < 0.001) hearing loss and tinnitus were associated with higher odds of reporting moderate to severe symptom interference scores in comparison to no hearing loss and tinnitus. This association of hearing dysfunction was consistent with all domains of HRQoL. Our findings provide preliminary evidence to support the need for continued audiological evaluations and surveillance to detect hearing dysfunction, to allow for early management and to alleviate the long-term impact on QoL.
Sections du résumé
BACKGROUND
This study investigated the association of hearing loss and tinnitus with overall health-related quality of life (HRQoL) among long-term oropharyngeal cancer (OPC) survivors.
METHODS
This study included OPC survivors treated between 2000 and 2013 and surveyed from September 2015 to July 2016. Hearing loss and tinnitus were measured by asking survivors to rate their "difficulty with hearing loss and/or ringing in the ears" from 0 (not present) to 10 (as bad as you can imagine). Hearing loss and tinnitus scores were categorized as follows: 0 for none, 1-4 for mild, and 5-10 for moderate to severe. The primary outcome was the mean score of MD nderson Symptom Inventory Head & Neck module interference component as a HRQoL surrogate dichotomized as follows: 0 to 4 for none to mild and 5 to 10 for moderate to severe interference.
RESULTS
Among 880 OPC survivors, 35.6% (314), reported none, 39.3% (347) reported mild, and 25.1% (221) reported moderate to severe hearing loss and tinnitus. On multivariable analysis, mild (OR, 5.83; 95% CI; 1.48-22.88; p = 0.012) and moderate (OR, 30.01; 95% CI; 7.96-113.10; p < 0.001) hearing loss and tinnitus were associated with higher odds of reporting moderate to severe symptom interference scores in comparison to no hearing loss and tinnitus. This association of hearing dysfunction was consistent with all domains of HRQoL.
CONCLUSIONS
Our findings provide preliminary evidence to support the need for continued audiological evaluations and surveillance to detect hearing dysfunction, to allow for early management and to alleviate the long-term impact on QoL.
Identifiants
pubmed: 35695117
doi: 10.1002/cam4.4931
pmc: PMC9844619
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
569-583Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Arch Otolaryngol Head Neck Surg. 2004 Apr;130(4):401-8
pubmed: 15096421
J Cancer Res Ther. 2018 Jul-Sep;14(5):1099-1104
pubmed: 30197356
Int J Audiol. 2003 Jul;42 Suppl 2:2S17-20
pubmed: 12918624
Oral Oncol. 2007 Feb;43(2):187-92
pubmed: 16860590
J Am Geriatr Soc. 1993 Apr;41(4):401-7
pubmed: 8463527
Front Oncol. 2020 Jan 22;9:1522
pubmed: 32039012
Pain. 1995 May;61(2):277-284
pubmed: 7659438
Laryngoscope. 2017 Jan;127(1):127-133
pubmed: 27392821
Phys Med. 2018 Jan;45:192-197
pubmed: 29329660
JAMA Otolaryngol Head Neck Surg. 2018 Nov 1;144(11):1066-1076
pubmed: 30193299
Head Neck. 2017 Oct;39(10):2114-2126
pubmed: 28766791
Cancer Med. 2023 Jan;12(1):569-583
pubmed: 35695117
Eur Arch Otorhinolaryngol. 2017 Dec;274(12):4183-4193
pubmed: 28940024
JAMA Ophthalmol. 2019 Nov 01;137(11):1317-1320
pubmed: 31580383
Br J Oral Maxillofac Surg. 2012 Dec;50(8):715-20
pubmed: 22326324
Support Care Cancer. 2021 Apr;29(4):1825-1835
pubmed: 32779007
Cancer. 2021 Dec 1;127(23):4470-4480
pubmed: 34358341
Int J Cancer. 2008 Jun 15;122(12):2656-64
pubmed: 18360824
JAMA Otolaryngol Head Neck Surg. 2015 Sep;141(9):810-5
pubmed: 26291150
Arch Intern Med. 2009 Feb 23;169(4):415-6
pubmed: 19237727
Laryngoscope Investig Otolaryngol. 2017 Mar 16;2(2):69-79
pubmed: 28894825
Pediatrics. 2006 Apr;117(4):1101-12
pubmed: 16585304
J Clin Oncol. 2011 Nov 10;29(32):4294-301
pubmed: 21969503
Clin Genitourin Cancer. 2014 Feb;12(1):41-9
pubmed: 24126238
Head Neck. 2015 Feb;37(2):281-92
pubmed: 24478269
Int J Audiol. 2009 Mar;48(3):117-22
pubmed: 19283583
JAMA Otolaryngol Head Neck Surg. 2021 Jul 1;147(7):615-623
pubmed: 33956062
Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1108-14
pubmed: 21640505
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Indian J Cancer. 2009 Oct-Dec;46(4):311-7
pubmed: 19749461
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1187-1196
pubmed: 27245751
J Psychosom Res. 1989;33(4):441-8
pubmed: 2795516
Gynecol Oncol. 2013 Aug;130(2):323-8
pubmed: 23685012
J Rehabil Res Dev. 2014;51(1):81-100
pubmed: 24805896
Oncol Rep. 2005 Jun;13(6):1193-9
pubmed: 15870942
Ann Intern Med. 1990 Aug 1;113(3):188-94
pubmed: 2197909
Cancer Chemother Pharmacol. 2020 Feb;85(2):245-250
pubmed: 31865419
Int J Cancer. 2003 Apr 10;104(3):336-44
pubmed: 12569557
J Laryngol Otol. 2019 Jan;133(1):18-25
pubmed: 30047343
Radiother Oncol. 2014 Mar;110(3):422-8
pubmed: 24582144
J Cancer Res Ther. 2018 Oct-Dec;14(6):1412-1417
pubmed: 30488865
Nat Rev Clin Oncol. 2009 Oct;6(10):567-8
pubmed: 19787001
BMC Geriatr. 2015 Feb 25;15:16
pubmed: 25879461
Int J Radiat Oncol Biol Phys. 2007 Feb 1;67(2):469-79
pubmed: 17236969
Am J Otolaryngol. 2006 Mar-Apr;27(2):76-80
pubmed: 16500467
Arch Otolaryngol Head Neck Surg. 2008 Mar;134(3):241-8
pubmed: 18347247
Gerontologist. 2020 Apr 2;60(3):e137-e154
pubmed: 30835787
J Med Imaging Radiat Sci. 2014 Sep;45(3):316-322
pubmed: 31051984
Arch Med Sci. 2014 Dec 22;10(6):1153-9
pubmed: 25624853
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3 Suppl):S50-7
pubmed: 20171518
Head Neck. 2000 Jul;22(4):398-407
pubmed: 10862025